期刊文献+

沙利度胺致月经不调 被引量:7

Irregular menstruation induced by thalidomide
暂未订购
导出
摘要 1例28岁女性患者,主诉左膝关节肿痛3年,腰背痛及左髋关节疼痛2年。左膝关节肿痛起病,腰背痛伴有晨僵及夜间痛,双足跟疼痛,无虹膜炎及强直性脊柱炎(AS)家族史。化验HLA-B27阳性,ESR 36 mm·h-1,CRP 3.48 mg·dL-1,骶髂关节CT示双侧骶髂关节虫蚀样改变,诊断为强直性脊柱炎,给予洛索洛芬钠及柳氮磺吡啶治疗后,患者左髋关节疼痛好转,但腰背痛症状改善不明显,加用沙利度胺(50 mg,qn),2周后给药剂量调至100 mg,qn。服用4个月后,腰背痛症状明显减轻,晨僵及夜间痛消失,但逐渐出现月经量减少至停经,停用沙利度胺2个月后症状好转。 One 28-year-old young female saw a doctor due to left knee joint pain and swelling for three years, low back painand left hip pain for two years. The patient had left knee joint pain and swelling, low back pain accompanied by morning stiffness andnocturnal back pain, as well as double heel pain. The patient had no history of iritis and family history of the ankylosing spondylitis(AS). HLA-B27 was positive, erythrocyte sedimentation rate was 36 mm·h-1, C-reactive protein was 3.48 mg·dL-1, and sacroiliacjoint CT showed bilateral sacroiliac joints erosion change. The patient was diagnosed with AS. Loxoprofen sodium and sulfasalazinewere given. The symptom of left hip pain improved after the treatment, but the low back pain did not obviously relieve. Thenthalidomide was given orally with the dose of 50 mg every night, and the dose was added to 100 mg after 2 weeks. Four months later,the symptom of low back pain significantly improved, morning stiffness and nocturnal back pain disappeared. But menstrual bloodvolume of the patient decreased gradually and subsequently the patient developed amenorrhea. Transvaginal ultrasonography showednormal. The symptoms improved after withdrawl of thalidomide for 2 months.
出处 《中国药物应用与监测》 CAS 2014年第1期55-57,共3页 Chinese Journal of Drug Application and Monitoring
关键词 沙利度胺 月经不调 药品不良反应 Thalidomide Irregular menstruation Adverse drug reaction
  • 相关文献

参考文献8

  • 1Hamuryudan V, Hatemi G, Tascilar K, et al. Prognosis of Behcet'ssyndrome among men with mucocutaneous involvement atdisease onset: long-term outcome of patients enrolled in acontrolled trial[J]. Rheumatology, 2010, 49(1): 173-177.
  • 2Cortés-Hernández J, Torres-Salido M, Castro-Marrero J, et al.Thalidomide in the treatment of refractory cutaneous lupuserythematosus: prognostic factors of clinical outcome[J]. Br JDermatol, 2012, 166(3): 616-623.
  • 3Yasui K. Thalidomide as immunomodulatory drug: pharmacologicalactions and its indications[J]. Nihon Rinsho MenekiGakkai Kaishi, 2010, 33(5): 229-233.
  • 4Majumder S, Sreedhara SR, Banerjee S, et al. TNF α signalingbeholds thalidomide saga: a review of mechanistic role of TNF-αsignaling under thalidomide[J]. Curr Top Med Chem, 2012,12(13): 1456-1467.
  • 5Huang F, Gu J, Zhao W, et al. One-year open-label trial ofthalidomide in ankylosing spondylitis[J]. Arthritis Rheum, 2002,47(3): 249-254.
  • 6Deng X, Zhang J, Zhang J, et al. Thalidomide reduces recurrenceof ankylosing spondylitis in patients following discontinuation ofetanercept[J]. Rheumatol Int, 2013, 33(6): 1409-1413.
  • 7Amirshahrokhi K. Anti-inflammatory effect of thalidomidein paraquat-induced pulmonary injury in mice[J]. IntImmunopharmacol, 2013, 17(2): 210-215.
  • 8Sharma GT, Dubey PK, Kumar GS. Effects of IGF-1, TGFalphaplus TGF-beta1 and bFGF on in vitro survival, growth andapoptosis in FSH-stimulated buffalo (Bubalis bubalus) preantralfollicles[J]. Growth Horm IGF Res, 2010, 20(4): 319-325.

同被引文献64

引证文献7

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部